Association between metabolic syndrome and transaminase levels
Keywords:
metabolic syndrome, occupational groups, transaminases, transferases.Abstract
Introduction: In the pathology of metabolic syndrome, manifestations of liver damage have been seen in different investigations and in clinical practice.Objective: To estimate the prevalence of elevated transaminases (alanine aminotransaminase and aspartate aminotransaminase), and to determine their association with metabolic syndrome. Methods: Cross-sectional with analytical procedure study. Secondary analysis of data generated by the electronic health record of an occupational polyclinic. The main variable was the diagnosis of metabolic syndrome. To define elevated aspartate aminotransaminase, values > 30 U/L in women and values > 36 U/L in men were considered. For alanine aminotransaminase, values > 30 U/L in women and values > 40 U/L in men were considered.
Results: The prevalence of metabolic syndrome was 21.82%, elevated aspartate aminotransaminase was 10.30% and elevated alanine aminotransaminase was 16.67%. In multiple regression, we adjusted for the confounding covariates of sex, age, occupation, body mass index, smoking, alcohol and physical activity. It was observed that patients with elevated aspartate aminotransaminase had a 128% higher frequency of presenting metabolic syndrome, compared to those without elevated values (reason prevalence= 2.28; 95% CI: 1.64-3.17; p< 0.001). On the other hand, it was found that patients with elevated alanine aminotransaminase had a 148% higher frequency of presenting metabolic syndrome compared to those without elevated values (reason prevalence= 2.48; 95% CI: 1.77 - 3.47; p< 0.001).
Conclusions: There is an association between elevated hepatic transaminases and the presence of metabolic syndrome.
Downloads
References
2. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018; 20(2):12. DOI: 10.1007/s11906-018-0812-z
3. Li R, Li W, Lun Z, Zhang H, Sun Z, Kanu JS, et al. Prevalence of metabolic syndrome in Mainland China: a meta-analysis of published studies. BMC Public Health. 2016; 16:296. DOI: 10.1186/s12889-016-2870-y
4. Hirode G, Wong RJ. Trends in the Prevalence of Metabolic Syndrome in the United States, 2011-2016. JAMA. 2020; 323(24):2526-8. DOI: 10.1001/jama.2020.4501
5. Márquez-Sandoval F, Macedo-Ojeda G, Viramontes-Hörner D, Fernández Ballart JD, Salas Salvadó J, Vizmanos B. The prevalence of metabolic syndrome in Latin America: a systematic review. Public Health Nutr. 2011; 14(10):1702-13. DOI: 10.1017/S1368980010003320
6. Tapia JC, Ruiz EF, Ponce OJ, Malaga G, Miranda J. Weaknesses in the reporting of cross-sectional studies according to the STROBE statement the case of metabolic syndrome in adults from Peru. Colombia Médica. 2015; 46(4):168-75. DOI: 10.2510/colomb
7. Arbañil-Huamán HC. Síndrome metabólico: Definición y prevalencia. Revista Peruana de Ginecología y Obstetricia. 2011 [acceso: 16/09/2021]; 57(4):233-6. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S2304-51322011000400004
8. Adams KJ, Chirinos JL. Prevalencia de factores de riesgo para síndrome metabólico y sus componentes en usuarios de comedores populares en un distrito de Lima, Perú. Revista Peruana de Medicina Experimental y Salud Pública. 2018; 35(1):39-45. DOI: 10.17843/rpmesp.2018.351.3598
9. Wang L, Du Z-H, Qiao J-M, Gao S. Association between metabolic syndrome and endometrial cancer risk: a systematic review and meta-analysis of observational studies. Aging (Albany NY). 2020; 12(10):9825-39. DOI: 10.18632/aging.103247
10. Zhang J, Wu H, Wang R. Metabolic syndrome and esophageal cancer risk: a systematic review and meta‑analysis. Diabetol Metab Syndr. 2021; 13(1):8. DOI: 10.1186/s13098-021-00627-6
11. Mariani M, Sassano M, Boccia S. Metabolic syndrome and gastric cancer risk: a systematic review and meta-analysis. Eur J Cancer Prev. 2021; 30(3):239-50. DOI: 10.1097/CEJ.0000000000000618
12. Myers J, Kokkinos P, Nyelin E. Physical Activity, Cardiorespiratory Fitness, and the Metabolic Syndrome. Nutrients. 2019; 11(7):E1652. DOI: 10.3390/nu11071652
13. Katsiki N, Perez-Martinez P, Anagnostis P, Mikhailidis DP, Karagiannis A. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome? Curr Vasc Pharmacol. 2018; 16(3):219-27. DOI: 10.2174/1570161115666170621075619
14. Wang J, Wang Y, Chen F, Ma G, Wang D. Measurement of the Combined Levels of Serum Uric Acid and Alanine Aminotransferase and the Risk of Metabolic Syndrome in a Population Aged 60 Years or More in Northeastern China. Med Sci Monit. 2020; 26:e916459. DOI: 10.12659/MSM.916459
15. Kunutsor SK, Apekey TA, Walley J. Liver aminotransferases and risk of incident type 2 diabetes: a systematic review and meta-analysis. Am J Epidemiol. 2013; 178(2):159-71. DOI: 10.1093/aje/kws469
16. Kunutsor SK, Apekey TA, Khan H. Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies. Atherosclerosis. 2014; 236(1):7-17. DOI: 10.1016/j.atherosclerosis.2014.06.006
17. Chen Y-F, Lin Y-A, Yeh W-C, Tsao Y-C, Li W-C, Fang W-C, et al. The Association between Metabolic Syndrome and Elevated Alanine Aminotransferase Levels in an Indigenous Population in Northern Taiwan: A Community-Based and Cross-Sectional Study. Evid Based Complement Alternat Med. 2020; 2020:6612447. DOI: 10.1155/2020/6612447
18. Chen K-W, Meng F-C, Shih Y-L, Su F-Y, Lin Y-P, Lin F, et al. Sex-Specific Association between Metabolic Abnormalities and Elevated Alanine Aminotransferase Levels in a Military Cohort: The CHIEF Study. Int J Environ Res Public Health. 2018; 15(3):E545. DOI: 10.3390/ijerph15030545
19. Zhang J, Wang Z-Y, Zhang J-P, Zhou H, Ding Z. Prevalence of Elevated Alanine Aminotransferase by Diagnostic Criterion, Age, and Gender among Adolescents. Gastroenterol Res Pract. 2020; 2020:4240380. DOI: 10.1155/2020/4240380
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-97. DOI: 10.1001/jama.285.19.2486v
21. Esteghamati A, Jamali A, Khalilzadeh O, Noshad S, Khalili M, Zandieh A, et al. Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound. Diabetol Metab Syndr. 2010; 2:65. DOI: 10.1186/1758-5996-2-65
22. Yamamoto JM, Prado-Núñez S, Guarnizo-Poma M, Lazaro-Alcantara H, Paico-Palacios S, Pantoja-Torres B, et al. Association between serum transaminase levels and insulin resistance in euthyroid and non-diabetic adults. Diabetes Metab Syndr. 2020; 14(1):17-21. DOI: 10.1016/j.dsx.2019.11.013
23. Kim HR, Han MA. Association between Serum Liver Enzymes and Metabolic Syndrome in Korean Adults. Int J Environ Res Public Health. 2018; 15(8):E1658. DOI: 10.3390/ijerph15081658
24. Yildirim B, Ozugurlu F, Sahin S, Ozyurt H, Atis O, Akbas A, et al. Association between elevated aminotransferase levels and the metabolic syndrome in Northern Turkey. Ann Hepatol. 2010 [acceso: 16/09/2021]; 9(2):161-5. Disponible en: https://pubmed.ncbi.nlm.nih.gov/20526009/
25. Villegas R, Xiang Y-B, Elasy T, Cai Q, Xu W, Li H, et al. Liver enzymes, type 2 diabetes, and metabolic syndrome in middle-aged, urban Chinese men. Metab Syndr Relat Disord. 2011; 9(4):305-11. DOI: 10.1089/met.2011.0016
26. Jiang W, Liu C-H, Wu D, Wang Y-J, Tang H. Abnormal transaminase and lipid profiles in coexisting diseases in patients with fatty liver: a population study in Sichuan. Biosci Rep. 2021; 41(12):BSR20211769. DOI: 10.1042/BSR20211769
27. Lizarzaburu Robles JC. Síndrome metabólico: concepto y aplicación práctica. An Fac med. 2014; 74(4):315. DOI: 10.15381/anales.v74i4.2705
28. Chen QC, Xiao J, Zhang PP, Chen LL, Chen XX, Wang SM. Longitudinal Changes in Liver Aminotransferases Predict Metabolic Syndrome in Chinese Patients with Nonviral Hepatitis. Biomed Environ Sci. 2016; 29(4):254-66. DOI: 10.3967/bes2016.033
29. Zhang L, Ma X, Jiang Z, Zhang K, Zhang M, Li Y, et al. Liver enzymes and metabolic syndrome: a large-scale case-control study. Oncotarget. 2015; 6(29):26782-8. DOI: 10.18632/oncotarget.5792
30. Chen S, Guo X, Yu S, Zhou Y, Li Z, Sun Y. Metabolic Syndrome and Serum Liver Enzymes in the General Chinese Population. Int J Environ Res Public Health. 2016; 13(2):223. DOI: 10.3390/ijerph13020223
31. Liu C-F, Zhou W-N, Lu Z, Wang X-T, Qiu Z-H. The associations between liver enzymes and the risk of metabolic syndrome in the elderly. Exp Gerontol. 2018; 106:132-6. DOI: 10.1016/j.exger.2018.02.026
32. Perera S, Lohsoonthorn V, Jiamjarasrangsi W, Lertmaharit S, Williams MA. Association Between Elevated Liver Enzymes and Metabolic Syndrome Among Thai Adults. Diabetes Metab Syndr. 2008; 2(3):171-8. DOI: 10.1016/j.dsx.2008.04.012
33. Aliabadi PK, Sohrab M, Hessami A, Afshari M, Kashi Z, Kheradmand M, et al. Association between liver enzymes and metabolic syndrome: results of the enrollment phase of Tabari cohort. Ir J Med Sci. 2022;191(3):1201-08. DOI: 10.1007/s11845-021-02694-0
34. Ou Y-L, Lai Y-R, Jiang C-N, Zhang J, Ding Z. Diagnostic performance of individual characteristics and anthropometric measurements in detecting elevated serum alanine aminotransferase among children and adolescents. BMC Pediatr. 2020; 20:131. DOI: 10.1186/s12887-020-02033-9
35. Ding Z, Zhang J, Deng C-Y, You Y-B, Zhou H. Association of body mass index with serum alanine aminotransferase in Chinese adolescents: a school-based cross-sectional study. Gastroenterol Rep (Oxf). 2020; 8(2):119-24. DOI: 10.1093/gastro/goz039
36. Bekkelund SI, Jorde R. Alanine Aminotransferase and Body Composition in Obese Men and Women. Dis Markers. 2019; 2019:1695874. DOI: 10.1155/2019/1695874
Published
How to Cite
Issue
Section
License
Authors who have publications with this Journal accept the following terms:
- The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
- The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
- Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.